Lung function decline in adults with stable cystic fibrosis (CF) was tied to high numbers of mature low-density neutrophils,…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Researchers are developing new inhalable nanoparticles designed to deliver RNA-based gene-editing therapeutics directly to the lungs, a study reports. Now…
Small changes in the shape of CFTR, the protein defective or absent in people with cystic fibrosis (CF), opened its…
Trikafta increased the production of the faulty CFTR protein in cystic fibrosis (CF) patients, but it remained in…
Exposure to traffic-related air pollution is an important predictor of early lung function decline in children and adolescents with…
Unique global changes in gene activity and protein production were linked to different types of mutations in the CFTR gene,…
Pulmonary exacerbations in adults with cystic fibrosis (CF) fall into three distinct groups based on inflammatory markers in…
Lipid levels in human saliva were found to be significantly linked to complications related to cystic fibrosis (CF) —…
CFTR modulators, approved therapies to treat cystic fibrosis (CF), showed antibacterial activity and enhanced the efficacy of some antibiotics…
Treatment with Trikafta improved insulin secretion and body weight within one year in people with cystic fibrosis (CF),…